Pharmacokinetic Study of Genasense in Subjects With Normal Renal Function, Mildly Impaired Renal Function, and Moderately Impaired Renal Function

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

November 30, 2007

Study Completion Date

September 30, 2009

Conditions

Normal Renal FunctionMildly Impaired Renal FunctionModerately Impaired Renal Function

Interventions

DRUG

Genasense (oblimersen, G3139)

3 mg/kg/day by intravenous infusion for up to 48 hours

Trial Locations (1)

DaVita Clinical Research, Minneapolis